Linked Life Data

20364438

Source:http://linkedlifedata.com/resource/pubmed/id/20364438

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2010-5-6
pubmed:abstractText
The anti-inflammatory activity associated with fish oil has been ascribed to the long-chain polyunsaturated fatty acids (LC-PUFA), predominantly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Here we examined the anti-inflammatory effects of two DHA-rich algal oils, which contain little EPA, and determined the contribution of the constituent fatty acids, particularly DHA and docosapentaenoic acid (DPAn-6). In vitro, lipopolysaccharide (LPS)-stimulated Interleukin-1 beta (IL-1beta) and Tumor Necrosis Factor-alpha (TNF-alpha) secretion in human peripheral blood mononuclear cells (PBMC) was inhibited with apparent relative potencies of DPAn-6 (most potent) > DHA > EPA. In addition, DPAn-6 decreased intracellular levels of cyclooxygenase-2 (COX-2) and was a potent inhibitor of pro-inflammatory prostaglandin E2 (PGE2) production. DHA/DPAn-6-rich DHA-S (DHA-S) algal oil was more effective at reducing edema in rats than DHA-rich DHA-T (DHA-T), suggesting that DPAn-6 has anti-inflammatory properties. Further in vivo analyses demonstrated that feeding DPAn-6 alone, provided as an ethyl ester, reduced paw edema to an extent approaching that of indomethacin and enhanced the anti-inflammatory activity of DHA when given in combination. Together, these results demonstrate that DPAn-6 has anti-inflammatory activity and enhances the effect of DHA in vitro and in vivo. Thus, DHA-S algal oil may have potential for use in anti-inflammatory applications.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1558-9307
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
45
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
375-84
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:20364438-Animals, pubmed-meshheading:20364438-Anti-Inflammatory Agents, pubmed-meshheading:20364438-Cells, Cultured, pubmed-meshheading:20364438-Disease Models, Animal, pubmed-meshheading:20364438-Docosahexaenoic Acids, pubmed-meshheading:20364438-Edema, pubmed-meshheading:20364438-Eicosapentaenoic Acid, pubmed-meshheading:20364438-Eukaryota, pubmed-meshheading:20364438-Fatty Acids, Unsaturated, pubmed-meshheading:20364438-Humans, pubmed-meshheading:20364438-Inflammation, pubmed-meshheading:20364438-Interleukin-1beta, pubmed-meshheading:20364438-Leukocytes, Mononuclear, pubmed-meshheading:20364438-Male, pubmed-meshheading:20364438-Oils, pubmed-meshheading:20364438-Rats, pubmed-meshheading:20364438-Rats, Sprague-Dawley, pubmed-meshheading:20364438-Tumor Necrosis Factor-alpha
pubmed:year
2010
pubmed:articleTitle
Docosahexaenoic acid (DHA) and docosapentaenoic acid (DPAn-6) algal oils reduce inflammatory mediators in human peripheral mononuclear cells in vitro and paw edema in vivo.
pubmed:affiliation
Martek Biosciences Corporation, 6480 Dobbin Road, Columbia, MD 21045, USA. jnauroth@martek.com
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't